Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

840.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 840.14
Bid (Size) 830.00 (1)
Ask (Size) 849.00 (4)
Prev. Close 840.14
Today's Range 840.14 - 840.14
52wk Range 668.00 - 853.97
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+16.61%
+16.61%
1 Month
+5.16%
+5.16%
3 Month
+0.79%
+0.79%
6 Month
+11.42%
+11.42%
1 Year
+13.15%
+13.15%

More News

Read More
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
11 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
3 biotech powerhouses poised to thrive amid sector rebound
Via MarketBeat
Topics ETFs
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Via The Motley Fool
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Via Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
Via InvestorPlace
Topics Stocks
Exposures US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Via InvestorPlace
Topics Economy
Exposures Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.